Understanding rituximab function and resistance: Implications for tailored therapy

Frontiers in Bioscience

Volumn 16, Issue 2, 2011, Pages 770-782

  Amoroso, Alfredo ^a   Hafsi, Sameh ^a,b   Militello, Loredana ^a   Russo, Alessia E ^a   Soua, Zohra ^b   Mazzarino, Maria C ^a   Stivala, Franca ^a   Libra, Massimo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF SOUSSE   (Tunisia)

Author keywords

Anti CD20; B cell NHL; Gene mutations; MAPK pathway; Resistance; Review

Indexed keywords

CD20 ANTIGEN; FAS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL X; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RITUXIMAB; STAT3 PROTEIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; B CELL LYMPHOMA; COMPLEMENT CLASSICAL PATHWAY; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; HUMAN; IMMUNOLOGY; METABOLISM; NONHODGKIN LYMPHOMA; REVIEW;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTIGENS, CD95; APOPTOSIS; BCL-X PROTEIN; COMPLEMENT PATHWAY, CLASSICAL; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SRC-FAMILY KINASES; STAT3 TRANSCRIPTION FACTOR;

EID: 79955015045     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3719     Document Type: Article

References (124)

1. J Ferlay, F Bray , P Pisani , DM Parkin, GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. version 2.0; IARCPress, Lyon (2004)
2. F Bray, R Sankila, J Ferlay, DM Parkin: Estimates of Cancer Incidence and Mortality in Europe in 1995. Eur J Cancer 38, 99-166 (2002) (Pubitemid 34031832)
3. E Zucca, E Roggero, N Maggi-Solcà, A Conconi, F Bertoni, I Reilly, D Castelli, E Pedrinis, JC Piffaretti, F Cavalli: Prevalence of Helicobacter pylori and hepatitis C virus infections among non-Hodgkin's lymphoma patients in Southern Switzerland. Haematologica 85, 147-53 (2000) (Pubitemid 30366657)
4. M Libra, D Gasparotto, A Gloghini, PM Navolanic, V De Re, A Carbone: Hepatitis C virus (HCV) I hepatitis C virus (HCV) infection and lymphoproliferative disorders. Front Biosci 1, 2460-71 (2005) (Pubitemid 40905250)
5. DA Landau, D Saadoun, LH Calabrese, P Cacoub: The pathophysiology of HCV induced B-cell clonal disorders. Autoimmun Rev 6, 581-7 (2007) (Pubitemid 47374619)
6. DS Viswanatha, A Dogan: Hepatitis C virus and lymphoma. J Clin Pathol 60, 1378-83 (2007) (Pubitemid 350247254)
7. H Mawardi, C Cutler, N Treister: Medical management update: Non-Hodgkin lymphoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107, 19-33 (2009)
8. VA Morrison: Evolution of R-CHOP therapy for older patients with diffuse large B-cell lymphoma. Expert Rev Anticancer Ther 8, 1651-8 (2008)
9. C Gisselbrecht: Use of rituximab in diffuse large Bcell lymphoma in the salvage setting. Br J Haematol 143, 607-21 (2008)
10. MC Winter, BW Hancock: Ten years of rituximab in NHL. Expert Opin Drug Saf 8, 223-35 (2009)
11. A Braun, T Neumann, P Oelzner, G Hein, HJ Gröne, M Ziemer, G Wolf: Cryoglobulinaemia type III with severe neuropathy and immune complex glomerulonephritis: remission after plasmapheresis and rituximab. Rheumatol Int 28, 503-6 (2008) (Pubitemid 351629481)
12. YT Becker, BN Becker, JD Pirsch, HW Sollinger: Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 4, 996-1001 (2004) (Pubitemid 38745599)
13. H Valleala, M Korpela, T Mottonen, T Hienonen-Kempas, M Kauppi, P Hannonen, M Leirisalo-Repo: Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients. Scand J Rheumatol 6, 1-5 (2009)
14. M Ramos-Casals, M Soto, M Cuadrado, M Khamashta: Rituximab in systemic lupus erythematosusA systematic Rituximab Molecular Function and Resistance 778 review of off-label use in 188 cases. Lupus 18, 767-76 (2009)
15. T Dörner, A Radbruch, GR Burmester: B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 5, 433-441 (2009)
16. C Traullé, BB Coiffier: Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma. Future Oncol 1, 297-306 (2005)
17. AR Jazirehi, B Bonavida: Cellular and molecular signal trasduction pathways modulated by Rituximab (Rituxan, anti-CD20 mAb) in non-Hodgkin's lymphomas: implications in chemosensitization and therapeutic intervention. Oncogene 24, 2121-43 (2005) (Pubitemid 40516580)
18. JH Kehrl, A Riva, GL Wilson, C Thévenin: Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. Immunol Today 15, 432-6 (1994) (Pubitemid 24272188)
19. TF Tedder, G McIntyre, SF Schlossman: Heterogeneity in the B1 (CD20) cell surface molecule expressed by human B-lymphocytes. Mol Immunol 25, 1321-30 (1988) (Pubitemid 19023146)
20. MD Hulett, E Pagler, JR Hornby, PM Hogarth, HJ Eyre, E Baker, J Crawford, GR Sutherland, SJ Ohms, CR Parish: Isolation, tissue distribution, and chromosomal localization of a novel testis-specific human fourtransmembrane gene related to CD20 and FcepsilonRIbeta. Biochem Biophys Res Commun 12, 374-9 (2001) (Pubitemid 32917523)
21. JP Deans, GL Schieven, GL Shu, MA Valentine, LA Gilliland, A Aruffo, EA Clark, JA Ledbetter: Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2. J Immunol 1, 4494-504 (1993) (Pubitemid 23318502)
22. JP Deans, SM Robbins, MJ Polyak, JA Savage: Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem 2, 344-8 (1998) (Pubitemid 28042215)
23. I Semac, C Palomba, K Kulangara, N Klages, G van Echten-Deckert, B Borisch, DC Hoessli: Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res 15, 534-40 (2003) (Pubitemid 36152518)
24. B Bonavida: Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 28, 3629-36 (2007) (Pubitemid 46842700)
25. TF Tedder, SF Schlossman: Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. J Biol Chem 15, 10009-15 (1988)
26. JK Bubien, LJ Zhou, PD Bell, RA Frizzell, TF Tedder: Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 121, 1121-32 (1993) (Pubitemid 23154272)
27. G Cartron, L Dacheux, G Salles, P Solal-Celigny, P Bardos, P Colombat, H Watier: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 1, 754-8 (2002) (Pubitemid 34525533)
28. E Hatjiharissi, L Xu, DD Santos, ZR Hunter, BT Ciccarelli, S Verselis, M Modica, Y Cao, RJ Manning, X Leleu, EA Dimmock, A Kortsaris, C Mitsiades, KC Anderson, EA Fox, SP Treon: Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 1, 2561-4 (2007) (Pubitemid 47523179)
29. WK Weng, R Levy: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 1, 3940-7 (2003) (Pubitemid 46606207)
30. A Inagaki, T Ishida, H Yano, T Ishii, S Kusumoto, A Ito, M Ri, F Mori, J Ding, H Komatsu, S Iida, R Ueda: Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximabinduced ADCC. Int J Cancer 1, 212-21 (2009)
31. ME Reff, K Carner, KS Chambers, PC Chinn, JE Leonard, R Raab, RA Newman, N Hanna, DR Anderson: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 15, 435-45 (1994) (Pubitemid 24030569)
32. EE Idusogie, LG Presta, H Gazzano-Santoro, K Totpal, PY Wong, M Ultsch, YG Meng, MG Mulkerrin: Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 15, 4178-84 (2000) (Pubitemid 30215076)
33. EE Idusogie, PY Wong, LG Presta, H Gazzano-Santoro, K Totpal, M Ultsch, MG Mulkerrin: Engineered antibodies with increased activity to recruit complement. J Immunol 15, 2571-5 (2001) (Pubitemid 32173494)
34. MJ Glennie, RR French, MS Cragg, RP Taylor: Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44, 3823-37 (2007) (Pubitemid 47332625)
35. O Manches, G Lui, L Chaperot, R Gressin, JP Molens, MC Jacob, JJ Sotto, D Leroux, JC Bensa, J Plumas: In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 1, 949-54 (2003) (Pubitemid 36139365)
36. K Koretz, S Brüderlein, C Henne, P Möller: Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium. Br J Cancer 68, 926-31 (1993) (Pubitemid 23315225)
37. H Inoue, M Mizuno, T Uesu, T Ueki, T Tsuji: Distribution of complement regulatory proteins, decayaccelerating factor, CD59/homologous restriction factor 20 and membrane cofactor protein in human colorectal adenoma and cancer. Acta Med Okayama 48, 271-7 (1994)
38. X Zhou, W Hu, X Qin: The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 13, 954-66 (2008)
39. K Takei, T Yamazaki, U Sawada, H Ishizuka, S Aizawa: Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk Res 30, 625-31 (2006) (Pubitemid 43374591)
40. Z Fishelson, N Donin, S Zell, S Schultz, M Kirschfink: Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40, 109-23 (2003) (Pubitemid 36959821)
41. J Golay, L Zaffaroni, T Vaccari, M Lazzari, GM Borleri, S Bernasconi, F Tedesco, A Rambaldi, M Introna: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 15, 3900-8 (2000) (Pubitemid 30412866)
42. SP Treon, C Mitsiades, N Mitsiades, G Young, D Doss, R Schlossman, KC Anderson: Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 24, 263-71 (2001) (Pubitemid 32479718)
43. N Di Gaetano, Y Xiao, E Erba, R Bassan, A Rambaldi, J Golay, M Introna: Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 114, 800-9 (2001) (Pubitemid 32953735)
44. W Hu, SP Ferris, RK Tweten, G Wu, S Radaeva, B Gao, RT Bronson, JA Halperin, X Qin: Rapid conditional targeted ablation of cells expressing human CD59 in transgenic mice by intermedilysin. Nat Med 14, 98-103 (2008)
45. W Wojciechowski, H Li, S Marshall, C Dell'Agnola, I Espinoza-Delgado: Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms. J Immunol 15, 7859-68 (2005) (Pubitemid 40806295)
46. B Jahrsdörfer, G Hartmann, E Racila, W Jackson, L Mühlenhoff, G Meinhardt, S Endres, BK Link, AM Krieg, GJ Weiner: CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 69, 81-8 (2001) (Pubitemid 32095121)
47. Y Reiter, Z Fishelson: Targeting of complement to tumor cells by heteroconjugates composed of antibodies and of the complement component C3b. J Immunol 15, 2771-7 (1989) (Pubitemid 19114894)
48. E Racila, BK Link, WK Weng, TE Witzig, S Ansell, MJ Maurer, J Huang, C Dahle, A Halwani, R Levy, GJ Weiner: A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 15, 6697-703 (2008)
49. LE van der Kolk, AJ Grillo-López, JW Baars, CE Hack, MH van Oers: Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 115, 807-11 (2001) (Pubitemid 34042897)
50. S Alas, C Emmanouilides, B Bonavida: Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7, 709-23 (2001) (Pubitemid 32707998)
51. MA Ghetie, H Bright, ES Vitetta: Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 1, 1392-8 (2001) (Pubitemid 32183764)
52. JC Byrd, S Kitada, IW Flinn, JL Aron, M Pearson, D Lucas, JC Reed: The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 1, 1038-43 (2002) (Pubitemid 34525569)
53. C Emmanouilides, AR Jazirehi, B Bonavida: Rituximabmediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother Radiopharm 17, 621-30 (2002) (Pubitemid 36025943)
54. MI Vega, S Huerta-Yepez, M Martinez-Paniagua, B Martinez-Miguel, R Hernandez-Pando, CR González-Bonilla, P Chinn, N Hanna, K Hariharan, AR Jazirehi, B Bonavida: Rituximab-mediated cell signaling and chemo/ immunosensitization of drug-resistant B-NHL is independent of its Fc functions. Clin Cancer Res 1, 6582-94 (2009)
55. LE van der Kolk, LM Evers, C Omene, SM Lens, S Lederman, RA van Lier, MH van Oers, Eldering E: CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia 16, 1735-44 (2002)
56. I Skvortsova, S Skvortsov, BA Popper, A Haidenberger, M Saurer, AR Gunkel, H Zwierzina, P Lukas: Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and-independent mechanisms. J Radiat Res 47, 183-96 (2006) (Pubitemid 44034037)
57. JP Deans, L Kalt, JA Ledbetter, GL Schieven, JB Bolen, P Johnson: Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem 22, 22632-8 (1995)
58. JP Deans, H Li, MJ Polyak: CD20-mediated apoptosis: signalling through lipid rafts. Immunology 107, 176-82 (2002) (Pubitemid 35279043)
59. TL Unruh, H Li, CM Mutch, N Shariat, L Grigoriou, R Sanyal, CB Brown, JP Deans: Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking. Immunology 116, 223-32 (2005) (Pubitemid 41368664)
60. T Brdicka, D Pavlistová, A Leo, E Bruyns, V Korínek, P Angelisová, J Scherer, A Shevchenko, I Hilgert, J Cerný, K Drbal, Y Kuramitsu, B Kornacker, V Horejsí, B Schraven: Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation. J Exp Med 1, 1591-604 (2000) (Pubitemid 30257355)
61. M Kawabuchi, Y Satomi, T Takao, Y Shimonishi, S Nada, K Nagai, A Tarakhovsky, M Okada: Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature 27, 999-1003 (2000) (Pubitemid 30243594)
62. MI Vega, S Huerta-Yepez, AR Jazirehi, H Garban, B Bonavida: Rituximab (chimeric anti-CD20) sensitizes BNHL cell lines to Fas-induced apoptosis. Oncogene (55), 8114-27 (2005) (Pubitemid 41759811)
63. AJ Stel, B Ten Cate, S Jacobs, JW Kok, DC Spierings, M Dondorff, W Helfrich, HC Kluin-Nelemans, LF de Leij, S Withoff, B J Kroesen: Fas receptor clustering an involvement of the death receptor pathway in rituximabmediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. J Immunol 15, 2287-95 (2007) (Pubitemid 46233427)
64. T Wieder, F Essmann, A Prokop, K Schmelz, K Schulze-Osthoff, R Beyaert, B Dörken, PT Daniel: Activation of caspase-8 in drug-induced apoptosis of Blymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 1, 1378-87 (2001) (Pubitemid 32183762)
65. A Demidem, T Lam , S Alas , K Hariharan , NHanna , B Bonavida : Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12, 177-86 (1997) (Pubitemid 27349961)
66. E Suzuki, K Umezawa, B Bonavida: Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to druginduced apoptosis. Oncogene 13, 6184-93 (2007) (Pubitemid 47414382)
67. N Borsellino, A Belldegrun, B Bonavida: Endogenous interleukin 6 is a resistance factor for cisdiamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 15, 4633-9 (1995)
68. Y Mizutani, B Bonavida, Y Nio, O Yoshida: Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNFalpha mRNA downregulation in tumor cell sensitization. J Urol 151, 1697-702 (1994)
69. VL Ng, MH Hurt, CL Fein, F Khayam-Bashi, J Marsh, WM Nunes, LW McPhaul, E Feigal, P Nelson, BG Herndier, B Shiramizu, GR Reyes, KE Fry, MS McGrath: IgMs produced by two acquired immune deficiency syndrome lymphoma cell lines: Ig binding specificity and VH-gene putative somatic mutation analysis. Blood 15, 1067-78 (1994)
70. S Alas, B Bonavida: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 1, 5137-4461 (2001)
71. M Vockerodt, B Haier, P Buttgereit, H Tesch, D Kube: The Epstein-Barr virus latent membrane protein 1 induces interleukin-10 in Burkitt's lymphoma cells but not in Hodgkin's cells involving the p38/SAPK2 pathway. Int J Cancer 15, 240-4 (1994)
72. IM Pedersen, AM Buhl, P Klausen, CH Geisler, J Jurlander: The chimeric anti-CD20 antibody rituximab induces apoptosis in Bcell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinasedependent mechanism. Blood 99, 1314-9 (2002) (Pubitemid 34547086)
73. MI Vega, S Huerta-Yepaz, H Garban, A Jazirehi, C Emmanouilides, B Bonavida: Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 29, 3530-40 (2004) (Pubitemid 38658419)
74. N Mori, D Prager: Activation of the interleukin-10 gene in the human T lymphoma line HuT 78: identification and characterization of NF-kappa B binding sites in the regulatory region of the interleukin-10 gene. Eur J Haematol 59, 162-70 (1997) (Pubitemid 27392092)
75. AR Jazirehi, XH Gan, S De Vos, C Emmanouilides, B Bonavida: Rituximab (anti-CD20) selectively modifies BclxL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2, 1183-93 (2003)
76. HH Lee, H Dadgostar, Q Cheng, J Shu, G Cheng: NFkappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA 96, 9136-41 (1999) (Pubitemid 29374720)
77. C Chen, LC Edelstein, C Gélinas: The Rel/NF-kappa B Family Directly Activates Expression of the Apoptosis Inhibitor Bcl-xL. Mol Cell Bio 20, 2687-95 (2000) (Pubitemid 30183487)
78. Q Chen, HH Lee, Y Li, TP Parks, G Cheng: Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-nB inhibition. Oncogene 5, 4936-40 (2000)
79. L Sevilla, A Zaldumbide, P Pognonec, KE Boulukos: Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NFkappaB, STAT and AP1 transcription factor families. Histol Histopathol 16, 595-601 (2001) (Pubitemid 32297657)
80. V Dixit, TW Mak: NF-kappaB signaling: many roads lead to Madrid. Cell 27, 615-9 (2002) (Pubitemid 35441244)
81. S Ghosh, M Karin: Missing pieces in the NF-kB puzzle. Cell 109 Suppl, S81-96 (2002)
82. M Karin, A Lin: NF-kappaB at the crossroads of life and death. Nat Immunol 3, 221-7 (2002)
83. M Karin: The regulation of AP-1 activity by mitogenactivated protein kinases. J Biol Chem 14, 16483-6 (1995)
84. JT Lee Jr, JA McCubrey: The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 16, 486-507 (2002) (Pubitemid 34449728)
85. AR Jazirehi, B Bonavida: Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 3, 71-84 (2004) (Pubitemid 39193680)
86. AR Jazirehi, B Bonavida: Cellular and molecular characterization of rituximab-resistant CD20+ NHL Ramos (Ramos RR1) and Daudi (Daudi RR1) clones: development of cross-resistance to cytotoxic stimuli. Blood 104, 11 (2004)
87. AR Jazirehi, S Huerta-Yepez, G Cheng, B Bonavida: Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic druginduced apoptosis. Cancer Res 1, 264-76 (2005) (Pubitemid 40070818)
88. S Fujioka, GM Sclabas, C Schmidt, J Niu, WA Frederick, QG Dong, JL Abbruzzese, DB Evans, C Baker, PJ Chiao: Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. Oncogene 6, 1365-70 (2003) (Pubitemid 36384598)
89. PA Baeuerle, T Henkel: Function and activation of NFkappa B in the immune system. Annu Rev Immunol 12, 141-79 (1994)
90. EG Wulczyn, D Krappmann, C Scheidereit: The NFkB/ Rel and IkB gene families; mediators of immune response and inflammation. J mol med 74, 749-69 (1996) (Pubitemid 26405603)
91. PJ Barnes, M. Karin: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 10, 1066-71 (1997) (Pubitemid 27163860)
92. PA Baeuerle: The inducible transcription activator NFkappa B: regulation by distinct protein subunits. Biochim Biophys Acta 16, 63-80 (1991) (Pubitemid 121007530)
93. U Siebenlist, G Franzoso, KL Brown: Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 10, 405-55 (1994)
94. S Miyamoto, IM Verma : Rel/NF-kB/IkB story. Adv Cancer Res 66, 255-92 (1995)
95. TD Gilmore: The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene 18, 6842-4 (1999)
96. M Karin, Y Ben-Neriah: Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18, 621-63 (2000) (Pubitemid 30365393)
97. K Yeung, P Janosch, B McFerran, DW Rose, H Mischak, JM Sedivy, W Kolch: Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol 20, 3079-85 (2000) (Pubitemid 30215020)
98. LC Cantley: The phosphoinositide 3-kinase pathway. Science 31, 1655-7 (2002) (Pubitemid 34579158)
99. A Goswami, P Ranganathan, VM Rangnekar: The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancerselective therapeutic target. Cancer Res 15, 2889-92 (2006)
100. A Toker, M Yoeli-Lerner: Akt signaling and cancer: surviving but not moving on. Cancer Res 66, 3963-3966 (2006)
101. ON Ozes, LD Mayo, JA Gustin, SR Pfeffer, LM Pfeffer, DB Donner: NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 2, 82-5 (1999)
102. M Osaki, MH Oshimura, Ito: PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9, 667-76 (2004) (Pubitemid 40941196)
103. E Arranz, M Robledo, B Martfnez, J Gallego, A Remain, C Rivas, J Benítez : Incidence of homogeneously staining regions in non-Hodgkin lymphomas. Cancer Genet Cytogenet 87, 1-3 (1996) (Pubitemid 26113595)
104. S Uddin, A Hussain, K Al-Hussein, LC Platanias, KG Bhatiaa: Inhibition of phosphatidylinositol 30-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochem Biophys Res Commun 30, 932-8 (2004) (Pubitemid 38887233)
105. S Cuni, P Perez-Aciego, G Perez-Chacon, JA Vargas, A Sanchez, FM Martin-Saavedra, S Ballester, J García-Marco, J Jordá, A Durántez: A sustained activation of PI3K/NFkappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 18, 1391-400 (2004) (Pubitemid 39136749)
106. MI Vega, S Huerta-Yepez, P Chinn, H Hariharan, N Hanna, B Bonavida: Rituximab-mediated molecular cell signaling via CD20 in B-NHL cell lines: autonomy from crosslinking with tumor FcRs. Blood 104, 11 (2004)
107. MI Vega, S Huerta-Yepez, AR Jazirehi, H Garban, B Bonavida: Rituximab-mediated inhibition of the transcription repressor Yin-Yang 1 (YY1) in NHL B cell lines: upregulation of Fas expression and sensitization to Fas-induced apoptosis. Blood 104, 11 (2004)
108. S Alas, B Bonavida: Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 9, 316-26 (2003) (Pubitemid 36109748)
109. S Alas, CP Ng, B Bonavida: Rituximab modifies the cisplatinmitochondrial signaling pathway, resulting in apoptosis in cisplatinresistant non-Hodgkin's lymphoma. Clin Cancer Res 8, 836-45 (2002) (Pubitemid 34742116)
110. AR Jazirehi, MI Vega, D Chatterjee, L Goodglick, B Bonavida: Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res 64, 7117-7126 (2004) (Pubitemid 39331025)
111. HJ Garbán, B Bonavida: Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J Immunol 1, 75-81 (2001) (Pubitemid 32567763)
112. S Huerta-Yepez, MI Vega, AR Jazirehi, H Garban, F Hongo, G Cheng, B Bonavida: Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene 24, 4993-5003 (2004) (Pubitemid 38938732)
113. TA Davis, AJ Grillo-Lopez, CA White, P McLaughlin, MS Czuczman, BK Link, DG Maloney, RL Weaver, J Rosenberg, R Levy: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18, 3135-43 (2000)
114. I Jilani, S O'Brien, T Manshuri, DA Thomas, VA Thomazy, M Imam, S Naeem, S Verstovsek, H Kantarjian, F Giles, M Keating, M Albitar: Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 15, 3514-20 (2003) (Pubitemid 37419939)
115. T Kinoshita, H Nagai, T Murate, H Saito: CD20-negative relapse in B-cell lymphoma after treatment with rituximab. J Clin Oncol 16, 3916 (1998) (Pubitemid 29001546)
116. AJ Ferreri, GP Dognini, C Verona, C Patriarca, C Doglioni, M Ponzoni: Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma. Haematologica 92, e1-2 (2007)
117. WL Zhao, L Wang, YH Liu, JS Yan, C Leboeuf, YY Liu, WL Wu, A Janin, Z Chen, SJ Chen: Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis. Exp Hematol 35, 1801-1811 (2007) (Pubitemid 350123661)
118. A Tomita, J Hiraga, H Kiyoi, M Ninomiya, T Sugimoto, M Ito, T Kinoshita, T Naoe: Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int J Hematol 86, 49-57 (2007) (Pubitemid 47204490)
119. M Binder, F Otto, R Mertelsmann, H Veelken, M Trepel: The epitope recognized by rituximab. Blood 15, 1975-8 (2006) (Pubitemid 44395009)
120. AR Jazirehi, MI Vega, B Bonavida: Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 1, 1270-81 (2007)
121. K Wanner, S Hipp, M Oelsner, I Ringshausen, C Bogner, C Peschel, T Decker: Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 134, 475-84 (2006) (Pubitemid 44141713)
122. AG Bader, SY Kang, L Zhao, PK Vogt: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5, 921-929 (2005) (Pubitemid 41766781)
123. TL Yuan, LC Cantley: PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497-510 (2008)
124. SH Olejniczak, FJ Hernandez-Ilizaliturri, JL Clements, MS Czuczman: Acquired resistance to rituximeb is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res 1, 1550-60 (2008) (Pubitemid 351413940)